NASHVILLE, Tenn. / Feb 29, 2024 / Business Wire / HealthStream, Inc. (the “Company”) (Nasdaq: HSTM), a leading healthcare technology platform for workforce solutions announced today that, as disclosed in the Company’s earnings release dated February 19, 2024, the Board of Directors has approved a 12 percent increase in the Company’s quarterly dividend to $0.028 per share, up from $0.025 per share—and declared a cash dividend for the first quarter of 2024 of $0.028 per share of the Company’s outstanding common stock. The first quarter 2024 dividend will be payable to stockholders of record as of the close of March 11, 2024, with a payment date of March 22, 2024.
“We are pleased that our operational performance and strong balance sheet allow us to return value directly to shareholders through HealthStream’s quarterly cash dividend program, which we launched last year,” said Robert A. Frist, Jr., Chief Executive Officer, HealthStream. “We will continue to manage our capital to optimize long-term value and meaningful results for shareholders.”
About HealthStream
HealthStream (Nasdaq: HSTM) is the healthcare industry’s largest ecosystem of platform-delivered workforce solutions that empowers healthcare professionals to do what they do best: deliver excellence in patient care. For more information about HealthStream, visit www.healthstream.com.
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact) that involve risks and uncertainties regarding HealthStream. These statements are based upon management’s beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including, without limitation, legal requirements and contractual restrictions which may affect the continuation of our quarterly cash dividend policy, which may be modified, suspended or canceled in any manner and at any time that our Board may deem necessary or appropriate, as well as risks referenced in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed on February 26, 2024, and in the Company’s other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.
Last Trade: | US$31.62 |
Daily Change: | 0.19 0.60 |
Daily Volume: | 36,335 |
Market Cap: | US$961.560M |
November 05, 2024 October 21, 2024 July 22, 2024 April 22, 2024 February 19, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB